Evidence map›Paper›PMID 16244192›Full record

ArticleBritish journal of sports medicine2005

Release of alpha-actin into serum after skeletal muscle damage.

A Martínez-Amat, H Boulaiz, J Prados, J A Marchal, P Padial Puche, O Caba, F Rodríguez-Serrano, A Aránega

Open access · bronzeAbstract read
In one paragraph

Article in British journal of sports medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Development aggravates the severity of skeletal muscle catabolism induced by endotoxemia in neonatal pigs.American journal of physiology. Regulatory, integrative and comparative physiology · 2012
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

A Martínez-AmatDepartment of Health Sciences, University of Jaén, E-23071 Jaén, Spain.
H Boulaiz
J Prados
J A Marchal
P Padial Puche
O Caba
F Rodríguez-Serrano
A Aránega
Universidad de Granada · ESUniversidad de Jaén · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe skeletal muscle protein alpha-actin was investigated in the serum of subjects with severe skeletal muscle damage to assess its utility as a reliable and predictive marker of muscle damage.

methodsSerum samples were obtained from 33 healthy controls and 33 patients with severe skeletal muscle damage, defined by a total creatine kinase value of >500 IU/l (Rosalki method). Troponin I, troponin T, and myoglobin concentrations were determined by immunoassay and alpha-actin concentrations by Western blot and densitometry.

resultsThe mean serum concentration of alpha-actin in controls and patients with skeletal muscle damage was 600.9 and 1968.51 ng/ml, respectively, a statistically significant difference. Sera of patients with muscle damage showed higher levels of alpha-actin than of troponin or myoglobin. No significant difference in troponin I levels was observed between the groups.

conclusionsAccording to these results, alpha-actin was the most significant skeletal muscle damage marker analysed and may be an ideal candidate for the identification of all types of myofibre injury, including sports injuries. Our findings support the use of alpha-actin as a marker alongside other currently used biological proteins.

Indexed as

ActinsAdultAgedAged, 80 and overAthletic InjuriesBiomarkersBlotting, WesternCreatine KinaseFemaleHumansMaleMiddle AgedMuscle, SkeletalMyoglobinTroponin ITroponin TActinsBiomarkersCreatine KinaseMyoglobinTroponin ITroponin T

Identifiers

PMID16244192
PMCPMC1725075
OpenAlexW2170939840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.